US 2019/0375783 A1 · SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM) REGIMEN

Abstract

The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β, 17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and/or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

Claims20

Dependent claims

A method for treating Heavy Menstrual Bleeding (HMB) by administering to a patient a pharmaceutical composition comprising (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one (Compound 1) of formula

or salts, solvates or solvates of the salts, including all crystal modifications thereof, comprising the steps of:
administering the pharmaceutical composition daily during a period of four (4) weeks to one (1) year, and
discontinuing the administration until one (1) or two (2) bleeding episodes occur.

Dependencies are inferred from the claim text.

Facts

Application

16/538,165Filed 12 Aug 2019

Priority

EP 15001475.118 May 2015

Published

12 Dec 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

C07J 31/006
Normal steroids containing one or more sulfur atoms not belonging to a hetero ring: not covered by C07J31/003
A61K 31/567
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61P 15/00
Drugs for genital or sexual disorders
C07J
Steroids

Family

Application15/575,088Division · filed 17 Nov 2017

Application16/214,515Division · filed 10 Dec 2018

Application16/538,165Division

US 10,858,388 B2Related patent

US 2018/0155388 A1Published application

US 2019/0211053 A1Published application

US 2019/0375783 A1This patent

From the US filing history. Foreign family members aren’t listed.

Selective progesterone receptor modulator (sprm) regimen

Life of this patent

Selective progesterone receptor modulator (sprm) regimen

Life of this patent

Abstract

Claims20